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The recently published review considers some of the scientific literature relating to the proposed relationship between the A1 and A2 variants of beta casein ('A1' and 'A2', respectively) and Type 1 diabetes mellitus (DM-1) and coronary heart disease (CHD). It extends also to discuss briefly the putative link between the beta casein variants and neurological conditions. The authors of this letter wish to introduce literature and data omitted by the said review believed to be relevant to the considerations presented and the conclusions drawn there from.
Type I diabetes mellitus
The published review provides a critique of selected epidemiology papers and a chronological synopsis of the research trials conducted in relation to DM-1. It is of note that Truswell arrives at a conclusion not collectively shared by the authors of the reviewed papers, and has omitted research reporting parallel correlations in more localised studies concerning Nordic countries (Birgisdottir et al., 2002) and regions of Germany (Wasmuth et al., 1999) .
The review accurately states that it is essential to confirm independently Elliott's experiments with NOD mice; it subsequently presents a multicentre trial as serving this purpose (Beales et al., 2002) . It is important to note that the animals in this trial had free access to cereal grains, a dietary component reported previously by one of the participating researchers as strongly diabetogenic (Scott, 1996) . Additionally, the pregestimil infant formula, which was included in four of eight of the experimental diets, contained a high amount of BCM 7; although not reported in the paper this has been publicly reported (Cone, 2002) and confirmed (Australian Broadcasting Corporation, 2003) . Considering the aforementioned, it would appear that the failure to provide a true 'control' may compromise the hypothesis tested and thus not adequately test for diabetogenic effects of A1 and A2 beta caseins. The presence of BCM-7 and grain-derived diabetogenic factor(s) is likely reflected in the results obtained, with 71 and 73% of the 'control' groups ofA notable omission from the review is research that presents data and discusses a proposed mechanism relating to beta casein and DM-1: pertaining to an antigenic determination mechanism. In a 1999 review (Pozzilli, 1999) , Pozzilli presents data implicating beta casein as a major antigenic determinant in the development of DM-1. Consistent with previous studies concerning beta casein A1, the paper reports a cell-mediated immune response, as well as the detection of antibodies, to beta casein in recent onset DM-1 patients. Although this study did not consider particular variants, a subsequent familial study measured and differentiated antibodies against A1 and A2 casein variants in four groups of people: IDDM patients, their siblings, individual parents, and healthy controls (Padberg et al., 1999) . It was found that antibodies against casein were present in all four groups, with the highest titres being found in diabetics. It is interesting, not to mention consistent with observations yielded by epidemiological studies, that increased amounts of anti-casein A1 antibodies were found among patients with IDDM and their siblings. On the other hand, the serum samples from parents and control persons contained antibodies against the A2 variant.
Coronary heart disease
In his review, Truswell identifies 'two hypotheses' based on nutritional literature linking milk consumption with CHD; one relating to the raising of serum cholesterol and the other to a possible serum cholesterol-lowering agent in milk.
Given these hypotheses, and the studies from which they stem, and their focus on milk, it may be viewed as misleading to present them when reviewing the effects of specific components of milk that are known to present in widely ranging concentrations. The beta casein variant content of milk is variable among regions as duly noted in Truswell's review, and it would be accurate to contend that further qualifications are required prior to considering the work cited with regard to the linkage under review. This applies also to the citing of research concerning milk consumption in Switzerland and CHD mortality, of which changes of beta casein allelic frequency in production herds have not been mentioned nor considered, an important omission given the propensity for gene frequencies to fluctuate in selective breeding and the founder-type effect from siring programmes.
Truswell continues and states incorrectly that 'no plausible mechanism has been put forward for a different influence on the pathogenesis of CHD between A1 and A2 Milk.' As noted in his review A1, but not A2, yields beta casomorphin-7 (BCM-7) (Jinsmaa and Yoshikawa, 1999) , a bioactive peptide that has been characterised not only as an opiate receptor agonist but as a peptide with the ability to catalyse the oxidation of LDL in a noncationdependent fashion (Torreilles and Guerin, 1995) . The uptake of oxidised LDL by endothelium-bound macrophages has been widely implicated in the pathogenesis of atherosclerosis (Siow et al., 1999) . Thus stated, a plausible biochemical mechanism relating to the relationship between A1 beta casein (not 'A1 milk') and CHD has been put forward (Tailford et al., 2003; Steinerova et al., 2004) . This hypothesis was raised and discussed in reports that cow's milk infant formula-fed infants raised antibodies to oxidised LDL (oxLDL) at 10 times the rate of those who were breast fed (Steinerova et al., 1999 (Steinerova et al., , 2001 (Steinerova et al., , 2004 . This observation, coupled with the reasoning of BCM-7 involvement, was further supplemented by the report where a distinction was made between a male and female baby's responses to infant formula feeding (milk protein), the former group exhibiting a highly significant increase (an order of magnitude) in antibodies to oxLDL in relation to breast feeding.
When commenting on the Tailford et al. (2003) paper, Truswell overlooks the reported observation that 10% A1, A2 and control feeding groups displayed significant differences in the stenosis, or thickening, of the aortic arch and restonisis of the carotid artery, or the thickening following endothelial injury. A2-fed groups were comparable to control groups, with A1-fed groups showing equivalent damage to that induced by 0.5% cholesterol feeding. What is of note is that milk protein devoid of A1 (A2-fed group) showed apparent attenuation of cholesterol-induced damage, an indication that bioactives derived from milk proteins other than A1 may impart desirable cardiovascular effect .
Beta casomorphin 7
The hypotheses relating to the linkages between A1 consumption and the range of reported biological and physiological effects pivot about the production, absorption and circulation of BCM-7.
BCM-7 is among a plethora of bioactives (Shah, 2000) , and one of a subset of exomorphins , that are encoded and have the potential to be yielded from milk proteins. A1-derived BCM-7, although displaying similar properties to exomorphins yielded by other milk proteins has been observed to have a longer half-life (Panksepp et al., 1984) , a characteristic reflected by reports that it has been detected intact in urine (Cade et al., 2000) . It is of note that exomorphins are encoded also in human breast milk proteins; however, they have been reported as having much lower activity than their bovine counterparts (Herrera-Marschitz et al., 1989) .
Peptides derived from caseins exhibiting BCM-7 immunoreactivity have been shown to be produced (Svedberg et al., 1985) , absorbed and detected in human plasma (Chabance et al., 1998) . Additionally, precursors to BCM-7 have been detected in the plasma of newborn cows following milk intake (Umbach et al., 1985) and in newborn, but not, in adult dogs (Singh et al., 1989) . This demonstrates the potential of BCM-7 to be transmitted into circulation following digestion, notably in newborn or young mammals. More convincing, however, with respect to humans is the report of 'large amounts' of BCM-7 in urine (Cade et al., 2000) of patients with neurological conditions, which decrease significantly following dialysis or the adoption of a caseinfree diet. The review authored by Truswell incorrectly states that 'the release of beta casomorphin 7 has not yet been demonstrated in human subjects'.
Further to this, studies have implicated BCM-7 to be transported across the blood-brain barrier (Banks and Kastin, 1987) in a carrier-facilitated (Sun et al., 2003) manner. An early study had suggested that fragments corresponding to casomorphins may cross the breast parenchyma-blood barrier into plasma and subsequently penetrate the bloodbrain barrier to reach the central nervous system (Nyberg et al., 1989) . Indeed, in a recent study, which puts forward putative biological/metabolic pathways in which (bovine milk-derived) casomorphins have been implicated as being related to apnoea in sudden infant death syndrome (Sun et al., 2003) .
Bovine beta casein link to neurological conditions
Prior to discussion it must be clarified that the hypothetical link between A1 consumption with autistic spectral disorder (ASD) and schizophrenia relates not to the cause of the condition but to the aggravation of symptoms associated with these neurological conditions. More specifically, the hypothesis states that the absorption of food-derived exomorphins such as beta casomorphin 7 (BCM 7) may aggravate symptoms associated with ASD or schizophrenia.
This hypothesis is the basis of 'dietary intervention' that excludes gluten and casein (Knivsberg et al., 2002 ) from the diet of ASD patients. The former, gluten, has been shown to release gliadamorphin, an exomorphin comparable in opioid activity to BCM-7. A number of laboratories in the United States and Europe offer urine tests, which determine the level of peptides including BCM 7 and other beta casomorphins to serve as an indication of the potential usefulness of dietary intervention in the treatment of ASD patients. One published study reports that a casein-and gluten-free diet was accompanied by improvement in 81% of autistic children within 3 months (Cade et al., 2000) .
Thus, a firm foundation of research supports a link between casein-derived exomorphins and symptoms associated with adolescent ASD and schizophrenia patients. Given the known and above-outlined properties of BCM-7, it could be further hypothesised that BCM-7 may contribute significantly to any effects imparted by milk-derived bioactives. Indeed, support for this hypothesis may be reflected in media items that reported a reduction in symptoms associated with ASD following the exclusion of A1 from milk consumed by ASD patients (Channel 7, 2003) .
Concluding comment
In summary, it can be stated that Truswell's review was indeed critical but far from comprehensive. The incomplete review of epidemiological studies relating to A1/A2 and diseases did not introduce any further data and identified reasons why results were 'far from conclusive', reasons common to the bulk of epidemiological studies concerning nutrient intake across a multitude of countries. Furthermore, aspects of animal studies selected to support his conclusion were not appropriately qualified nor presented in a balanced manner.
It is noteworthy that a significant base of research was omitted by the review in the consideration of hypotheses linking beta caseins with adverse effects in humans. The exclusion of a number of relevant studies resulted in: an incomplete summary of research relating to DM-1 and CHD; an incorrect statement relating to the proposed mechanism of A1-mediated damage in CHD; and a complete omission, or oversight, of research that has yielded results that serve to underscore the proposed relationship between the consumption of beta caseins with the aggravation of neurological conditions.
Although a great amount of work must be undertaken to test the range of hypotheses associated with beta casein variants, it is somewhat premature to dismiss such hypotheses on the basis of the incomplete data set recently presented by Truswell. Furthermore, given the impact that the noted relationships may have on public health and quality of life of families with ASD children, it would be more prudent to encourage further research into the proposed relationships as opposed to drawing a seemingly impulsive conclusion to hypotheses drawn from, and supported by, epidemiological analysis, animal studies and studies into the biochemistry of milk-derived bioactive peptides.
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The three paragraphs under 'Epidemiology' in KB Woodford's long letter discuss which of several between-country studies are likely to be more reliable. He favours those published by originators of the A1/A2 hypothesis. I favour others that have included more countries (including the Netherlands and Ireland) and FAO food consumption data. As I wrote 'There is more uncertainty with national figures for A1 beta casein than for total milk casein and more uncertainties for these than for average milk consumption.' For infants consumption (considered with type 1 diabetes) there are the special problems that infant formulas usually contain increased whey and reduced casein and the milk protein used for their manufacture does not always come from within the country where the formulas are consumed. Correlation studies of national food intake against chronic diseases have been notoriously unreliable in nutrition research (and I gave some classic examples).
Answering the next paragraph Milk chemistry & pharmacology, there are, as I wrote, reports that BCM-7 can be released from cows milk A1 beta casein by IN VITRO digestion with three enzymes. But, I have not yet seen clear evidence that this peptide is released and active in humans in vivo. See for example Svedberg et al. (1985) found peptides in the human small intestine after 1 l of bovine milk that reacted immunologically as if beta-casomorphin 7 but it did not show opioid activity or behave chromatographically as authentic beta-casomorphin-7. Effects in animals, injecting
